
According to Benzinga Pro data, during Q4, bluebird bio (NASDAQ:BLUE) posted sales of $1.61 million. Earnings were up 28.49%, but bluebird bio still reported an overall loss of $155.05 million. bluebird bio collected $22.68 million in revenue during Q3, but reported earnings showed a $216.82 million loss.